PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Companyâs Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
äŒæ¥ã³ãŒãPEPG
äŒç€ŸåPepGen Inc
äžå Žæ¥May 06, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMcArthur (James G)
åŸæ¥å¡æ°81
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 06
æ¬ç€Ÿæåšå°245 Main St, 2nd Floor
éœåžCAMBRIDGE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·02142
é»è©±çªå·17034568000
ãŠã§ããµã€ãhttps://pepgen.com
äŒæ¥ã³ãŒãPEPG
äžå Žæ¥May 06, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMcArthur (James G)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã